Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?

PharmacoEconomics

Volumn 32, Issue 8, 2014, Pages 729-733

  Chambers, James D ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; FLUTICASONE PROPIONATE PLUS SALMETEROL; LIRAGLUTIDE; SOFOSBUVIR;

ACCOUNTABLE CARE ORGANIZATION; BLUE CROSS BLUE SHIELD; BUDGET; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; MANAGED CARE; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; MEDICARE; NOTE; PHARMACEUTICAL CARE; PHARMACY BENEFIT MANAGER; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PROSPECTIVE PAYMENT; PUBLIC HEALTH SERVICE; PUBLICATION; RISK FACTOR; STANDARDIZATION; UNITED STATES; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST; COST BENEFIT ANALYSIS; ECONOMICS; INSURANCE; TRENDS;

COST SHARING; COST-BENEFIT ANALYSIS; DRUG COSTS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 84906936861     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0166-6     Document Type: Note

References (47)

1. Leaf A. Cost effectiveness as a criterion for Medicare coverage. N Engl J Med. 1989;321(13):898-900.
2. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med. 2005;353(14):1516-22. (Pubitemid 41400929)
3. Prosser LA, Koplan JP, Neumann PJ, Weinstein MC. Barriers to using cost-effectiveness analysis in managed care decision making. Am J Manag Care. 2000;6(2):173-9. (Pubitemid 30260764)
4. Neumann PJ, Palmer JA, Daniels N, Quigley K, Gold MR, Chao S. A strategic plan for integrating cost-effectiveness analysis into the US healthcare system. Am J Manag Care. 2008;14(4):185-8. (Pubitemid 351501856)
5. Bryan S, Sofaer S, Siegelberg T, Gold M. Has the time come for cost-effectiveness analysis in US health care? Health Econ Policy Law. 2009;4(Pt 4):425-43.
6. Lee TH, Emanuel EJ. Tier 4 drugs and the fraying of the social compact. N Engl J Med. 2008;359(4):333-5.
7. Cunningham PJ. The growing financial burden of health care: national and state trends, 2001-2006. Health Aff (Millwood). 2010;29(5):1037-44.
8. Collins SR, Robertson R, Garber T, Doty MM. Insuring the future: current trends in health coverage and the effects of implementing the Affordable Care Act. The Commonwealth Fund. http://www.commonwealthfund.org/Publications/Fund- Reports/2013/Apr/Insuring-the-Future.aspx. Accessed 6 April 2014.
9. Express Scripts. 2014 Drugs not covered. https://member.express-scripts. com/images/pdf/2014prefdrugexclusionlist.pdf. Accessed 6 April 2014.
10. Kelly C. Express scripts tightens commercial formulary control with "not covered" list. The Pink Sheet. 7 October 2013.
11. CVS Caremark. Formulary Exclusions 2012. http://www.caremark.com/portal/ asset/Formulary-Exclusion-Drug-List-2012.pdf. Accessed 6 April 2014.
12. CVS Caremark. Formulary Drug Exclusions 2014. http://www.caremark.com/ portal/asset/cvscaremark-standard-formulary-drug-removal.pdf. Accessed 6 April 2014.
13. Kelly C. CVS Caremark formulary exclusion program expected to save $1 bil. In 2014. The Pink Sheet. 20 December 2013.
14. Silverman E. Bye, bye co-pay cards? Why express scripts is excluding dozens of drugs. http://www.forbes.com/sites/edsilverman/2013/10/21/bye-bye-co- pay-cards-why-express-scripts-is-excluding-dozens-of-drugs/. 21 October 2013. Accessed 6 April 2014.
15. Bach PB, Saltz LB, Wittes RE. In cancer care, cost matters. New York Times. http://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000- a-month-cancer-drug.html?-r=0.14 October 2012. Accessed 6 April 2014.
16. Pollack A. Sanofi halves price of cancer drug Zaltrap after Sloan-Kettering rejection. http://www.nytimes.com/2012/11/09/business/sanofi- halves-price-of-drug-after-sloan-kettering-balks-at-payingit.html. 11 August 2012. Accessed 6 April 2014.
17. Department of Veteran Affairs. Department of Veteran Affairs Health Economic Resource Center (HERC). http://www.herc.research.va.gov/home/default. asp. Accessed 6 April 2014.
18. Department of Defense. The Department of Defense (DoD) PharmacoEconomic Center (PEC). http://www.pec.ha.osd.mil/. Accessed 6 April 2014.
19. Washington State. Washington State Health Authority Health Technology Assessment Program. http://www.hca.wa.gov/hta/Pages/index.aspx. Accessed 6 April 2014.
20. Chambers JD, Neumann PJ. Listening to Provenge - what a costly cancer treatment says about future Medicare policy. N Engl J Med. 2011;364(18):1687-9.
21. Centers for Medicare and Medicaid Services. Decision memo for screening for the human immunodeficiency virus (HIV) infection (CAG-00409N). http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx? NCAId=229&NcaName=Screening+for+the+Human+Immunodeficiency+Virus+%28HIV%29 +Infection&bc=AiAAAAAACAAAAA%3d%3d&. Available 8 December 2009. Accessed 6 April 2014.
22. Centers for Medicare and Medicaid Services. Decision memo for screening for depression in adults (CAG-00425N). http://www.cms.gov/medicare-coverage- database/details/nca-decision-memo.aspx?NCAId=251&NcaName= Screening+for+Depression+in+Adults&bc=AiAAAAAACAAAAA%3d%3d&. Available 14 October 2011. Accessed 6 April 2014.
23. Centers for Medicare and Medicaid Services. Decision memo for screening and behavioral counseling interventions in primary care to reduce alcohol misuse (CAG-00427N). http://www.cms.gov/medicare-coverage-database/details/nca- decision-memo.aspx?NCAId=249. Available 14 October 2011. Accessed 6 April 2014.
24. Neumann PJ, Chambers JD. Medicare's enduring struggle to define "reasonable and necessary" care. N Engl J Med. 2012;367(19):1775-7.
25. Academy of Managed Care Pharmacy. The AMCP format for formulary submissions version 3.0. J Manag Care Pharm. 2010;16(1 Suppl A):1-30.
26. Wellpoint Health Technology Assessment Guidelines. Drug submission guidelines for re-evaluation of products, indications, and formulations. National Pharmacy and Therapeutics Committee. 2008. http://www.elsevierbi.com/~/ media/Images/Publications/Archive/The%20Pink%20Sheet/70/043/00700430001/ wellpoint-formulary-guidelines.pdf. Accessed 6 April 2014.
27. Watkins J, Sullivan SD, Wong E, Yamamoto S, Vogeler C, Ramsey S. Implementing a value-based formulary pilot in a U.S. Commercial Self-insured Group. Presented at the international society for pharmacoeconomics and outcomes research, Baltimore, MD, USA. 2011.
28. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302(13):1437-43.
29. Cebul RD, Rebitzer JB, Taylor LJ, Votruba M. Organizational fragmentation and care quality in the U.S. health care system. National Bureau of economic research working paper series 2008 August, Working Paper 14212.
30. Elhauge E. The fragmentation of U.S. health care: causes and solutions. Oxford: Oxford University Press; 2010.
31. Botta MD, Blendon RJ, Benson JM. Cost-effectiveness decision making and US public opinion. JAMA Intern Med. 2013;7:10.
32. Orient JM. Is the payment board a death panel? http://www. washingtontimes.com/news/2012/mar/8/is-the-payment-board-a-death-panel/?page= all. Available 3 Aug 2012.
33. The Patient Protection and Affordable Care Act, PL 111-148. 3-23-2010.
34. Selby J. Straight talk with...Joe Selby. Nat Med. 2012;18(8):1164.
35. Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N Engl J Med. 2010;363(16):1495-7.
36. The 2nd Panel on Cost-Effectiveness in Health and Medicine. http://2ndcep.hsrc.ucsd.edu/ (2014). Accessed 6 April 2014.
37. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
38. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276(14):1172-7. (Pubitemid 26329746)
39. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on costeffectiveness in health and medicine. JAMA. 1996;276(16):1339-41. (Pubitemid 26346934)
40. Phillips KA, Chen JL. Impact of the U.S. panel on cost-effectiveness in health and medicine. Am J Prev Med. 2002;22(2):98-105. (Pubitemid 34119123)
41. Cutler D. Analysis & commentary. How health care reform must bend the cost curve. Health Aff (Millwood). 2010;29(6):1131-5.
42. Chambers JD, Weiner DE, Bliss SK, Neumann PJ. What can we learn from the U.S. expanded end-stage renal disease bundle? Health Policy. 2013;110(2-3):164-71.
43. Miller HD. From volume to value: better ways to pay for health care. Health Aff (Millwood). 2009;28(5):1418-28.
44. McClellan M, McKethan AN, Lewis JL, Roski J, Fisher ES. A national strategy to put accountable care into practice. Health Aff (Millwood). 2010;29(5):982-90.
45. Institute for Clinical and Economic Review. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection. http://ctaf.org/sites/default/files/assessments/CTAF- Hep-C-Apr14-final.pdf (2014). Accessed 15 April 2014.
46. Centers for Disease Control. Hepatitis C FAQs for health professionals. http://www.cdc.gov/hepatitis/c/cfaq.htm (2014). Accessed 6 April 2014.
47. Reinhardt UE. The dollar value of an extra year of life. New York Times, 28 March 2014. http://economix.blogs.nytimes.com/2014/03/28/the-dollar-value-of- an-extra-year-of-life/?-php=true&-type=blogs&-r=0. Accessed 6 April 2014.